Premium
Pharmacokinetics of Daptomycin in a Critically Ill Adolescent with Vancomycin‐Resistant Enterococcal Endocarditis
Author(s) -
Akins Ronda L.,
Haase Mark R.,
Levy Eric N.
Publication year - 2006
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.26.5.694
Subject(s) - daptomycin , pharmacokinetics , endocarditis , medicine , vancomycin , dosing , enterococcus faecium , enterococcus , antibiotics , lipopeptide , intensive care medicine , pharmacology , microbiology and biotechnology , biology , staphylococcus aureus , bacteria , genetics
Daptomycin is a lipopeptide antibiotic active against multidrug‐resistant gram‐positive organisms. Our search of the literature found no published pediatric pharmacokinetic data. We report the use and pharmacokinetic analysis of daptomycin in a 13‐year‐old boy with vancomycin‐resistant Enterococcus faecium endocarditis. Pharmacokinetic parameters were found to be significantly different from published adult parameters, such as a faster elimination rate, shorter half‐life, and increased clearance. These age‐related differences in the pharmacokinetic profile of daptomycin have significant dosing implications. As the use of this drug for off‐label indications and in pediatric populations increases, it is important for clinicians to better understand the drug's pharmacokinetic profile in these patient populations.